Quantitative measurement of HER2 levels by multiplexed mass spectrometry from FFPE tissue predicts survival in patients treated with anti-HER2 based therapy

被引：0
|
作者：
Nuciforo, Paolo [1 ]
Thyparambil, Sheeno [2 ]
Aura, Claudia [1 ]
Garrido-Castro, Ana [1 ]
Peg, Vicente [1 ]
Jimenez, Jose [1 ]
Hoos, William [2 ]
Burrows, Jon [2 ]
Hembrough, Todd [2 ]
Perez-Garcia, Jose [1 ]
Cortes, Javier [1 ]
Scaltriti, Maurizio [3 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Oncoplex Diagnost, Rockville, MD USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-11-29
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prediction of HER2 positive breast cancer patients' response to anti-HER2 therapy using mRNA level
    Atallah, N.
    Makhlouf, S.
    Li, X. M.
    Zhangy, Y.
    Rakha, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 114 - 114
  • [22] BREAST CANCER BIOMARKERS AND HER2 TESTING AFTER 10 YEARS OF ANTI-HER2 THERAPY
    Ross, Jeffrey S.
    DRUG NEWS & PERSPECTIVES, 2009, 22 (02) : 93 - 106
  • [23] HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
    Alison E. Smith
    Emanuela Ferraro
    Anton Safonov
    Cristina Bernado Morales
    Enrique J. Arenas Lahuerta
    Qing Li
    Amanda Kulick
    Dara Ross
    David B. Solit
    Elisa de Stanchina
    Jorge Reis-Filho
    Neal Rosen
    Joaquín Arribas
    Pedram Razavi
    Sarat Chandarlapaty
    Nature Communications, 12
  • [24] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    LABORATORY INVESTIGATION, 2018, 98 : 91 - 91
  • [25] Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
    Yang, Liu
    Li, Wenfei
    Lu, Zhihao
    Lu, Ming
    Zhou, Jun
    Peng, Zhi
    Zhang, Xiaotian
    Wang, Xicheng
    Shen, Lin
    Li, Jian
    BMC CANCER, 2022, 22 (01)
  • [26] Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
    Liu Yang
    Wenfei Li
    Zhihao Lu
    Ming Lu
    Jun Zhou
    Zhi Peng
    Xiaotian Zhang
    Xicheng Wang
    Lin Shen
    Jian Li
    BMC Cancer, 22
  • [27] Quantitative diagnostic technology for HER2 positive breast cancer by molecular imaging: The potential predictive factor of anti-HER2 therapy
    Miyashita, M.
    Gonda, K.
    Tada, H.
    Watanabe, M.
    Ishida, T.
    Sasano, H.
    Ohuchi, N.
    CANCER RESEARCH, 2013, 73
  • [28] The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment
    Foged, Niels T.
    Brugmann, Anja
    Jorgensen, Jan T.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2013, 13 (03) : 233 - 242
  • [29] A novel method of measuring exosomal HER2 to assist in selecting advanced gastric cancer patients benefiting from anti-HER2 therapy
    Li, Q.
    Xu, X.
    Yu, Y.
    Li, W.
    Liang, L.
    Song, J.
    Zhao, X.
    Cai, S.
    Liu, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy
    Jiang, Z.
    Li, L.
    Liu, Y.
    Wang, T.
    Zhang, S.
    Yuan, Y.
    Bian, L.
    Liu, Q.
    Qi, F.
    CANCER RESEARCH, 2013, 73
12345